BSV-Portfolio-MoatBiotechnology

Moat Biotechnology

Life Sciences

Moat Biotechnology has created a novel second-generation single cycle-adenovirus vaccine platform technology (SC-AdVax) licensed from Mayo Clinic for the rapid development of nasal/oral vaccines for multiple infectious disease targets and cancer.

Why we invested:

BSV-Portfolio-Moat-MarketNeed

Market Need

Moat Biotechnology is targeting the recognized need for an intranasal vaccine for COVID-19 and other respiratory diseases. By encountering respiratory viruses at the nasal passage, it will be possible to significantly reduce their ability to replicate systemically within the body, where more serious viral morbidities occur.

BSV-Portfolio-Moat-SuperiorTech

Superior Technology

Moat Biotechnology’s technology stops pathogens at the point of entry, a significant advancement over existing vaccine platforms including mRNA. The Company possesses a powerful patent portfolio to protect the SC-AdVax platform.

BSV-Portfolio-Moat-Team-V2

Founder & Team

CEO Scott Rollins, PhD and COO Russell Rother, PhD invented Soliris, which was eventually sold to Astra Zeneca for $38 billion. They co-founded Selexys, which was sold to Novartis for $665 million. They are currently CEO and COO, respectively, of Tetherex Pharmaceuticals, from which Moat Biotechnology was recently spun out as a separate company.

Question? Just schedule a call with the BSV team.